Roche Reports Phase 2 Results for Polivy in Relapsed/Refractory Follicular Lymphoma

Roche today announced Phase 2 trial results for Polivy (polatuzumab vedotin) plus obinutuzumab in patients with relapsed or refractory follicular lymphoma. The trial demonstrated an overall response rate of 76%, with a complete response rate of 55%. These results support further development of Polivy in follicular lymphoma.